

## The Clinical Use of Brain SPECT Imaging in Neuropsychiatry

Daniel G. Amen, M.D.<sup>1</sup>, Joseph C. Wu, M.D.<sup>2</sup>, Blake Carmichael, Ph.D.<sup>3</sup>,

<sup>1</sup> The Amen Clinics, Newport Beach and Fairfield, CA. <sup>2</sup> Director, Brain Imaging Center, UC, Irvine <sup>3</sup> Department of Psychology, UC, Davis

### Correspondencia:

The Amen Clinics  
4019 Westerly Place, Suite 100, Newport Beach, CA 92660  
(949) 266-3700 Fax (949) 266-3750  
[docamen@aol.com](mailto:docamen@aol.com)

### Cita/Reference:

Amen, Daniel G., MD, WU, Joseph C, MD. and Carmichael Blake, MD. The Clinical Use of Brain SPECT Imaging in Neuropsychiatry. Alasbimn Journal 5(19): January 2003.  
<http://www.alasbimnjournal.cl/revistas/19/amen.html>

### ABSTRACT

This article reviews the literature on brain SPECT imaging in brain trauma, dementia, and temporal lobe epilepsy. Brain SPECT allows clinicians the ability to view cerebral areas of healthy, low, and excessive perfusion. This information can be correlated with what is known about the function or dysfunction of each area. SPECT has a number of advantages over other imaging techniques, including wider availability, lower cost, and high quality resolution with multi-headed cameras. There are a number of issues that compromise the effective use of SPECT, including low quality of some imaging cameras, and variability of image rendering and readings.


### INTRODUCTION

Despite a vast literature on functional brain imaging in areas relevant to neuropsychiatry, the clinical utilization of SPECT, PET, QEEG, and fMRI remains limited. This article will review the literature on the usefulness, limitations, and controversies of using brain single photon emission computed tomography (SPECT) imaging in neuropsychiatric practice, especially as it applies to brain trauma, dementia, and temporal lobe epilepsy.

Brain SPECT imaging is a nuclear medicine study that uses isotopes bound to neuro-specific pharmaceuticals to evaluate regional cerebral blood flow (rCBF) and indirectly metabolic activity<sup>(1)</sup>. Currently in the U.S. there are three available radiopharmaceuticals, xenon gas, HMPAO (Ceretek) and ECD (Neurolite). Xenon can provide absolute quantification of rCBF but is cumbersome in clinical settings. HMPAO and ECD provide a moment-in-time image of relative rCBF, where each patient acts as his or her own control. Relative rCBF means that after the study is performed the processing computer takes the pixel with the greatest number of counts, makes it equivalent to 100 and then scales everything to it. The most intense pixel is usually found in the cerebellum on SPECT with HMPAO<sup>(2)</sup> and in the medial occipital lobe with ECD<sup>(3)</sup>. The hallmark of a normal study is symmetrical perfusion<sup>(4)</sup>.

A widely held misconception is that the clinical use of SPECT is restricted by limited resolution<sup>(5)</sup>. Early SPECT practice utilized single-headed cameras that produced low resolution images, especially in deep areas of the brain. However, sophisticated multi-headed gamma detectors with fan beam collimators have been available for the past decade. George reports that multi-head SPECT camera resolution is similar to PET at considerably less cost<sup>(6)</sup>. One of the significant problems with SPECT in clinical practice is the variability of the imaging gamma cameras and subsequent variability in the quality of the obtained images. Also, image renderings vary from clinic to clinic. Some clinics provide minuscule gray scale horizontal, coronal, and sagittal SPECT slices on x-ray film. These images are difficult to interpret, even by experienced nuclear clinicians. Current manufacturers provide software for three-dimensional renderings that allow for more detailed and understandable images.

Another area of criticism of SPECT has been the issue of radiation exposure, especially in children. However, the average radiation exposure for one SPECT scan is 0.7rem (i.e., similar to a nuclear bone scan or brain CT) and is a safe procedure according to the guidelines established by the American Academy of Neurology<sup>(7)</sup>. The latter procedures are routinely ordered for many common medical conditions (i.e., bone fractures or head trauma), further suggesting that these levels of radiation exposure are generally acceptable in medical practice when indicated.



alasbimn journal

Indice/Index

Números anteriores  
Back issues

Enviar colaboraciones  
Instructions to authors

Sitios de interés  
Links



E-mail

Another concern about SPECT imaging is the perceived lack of "normal" studies. In order to address this issue, the Society of Nuclear Medicine has established a large normative database at Yale University for clinician and researcher use ([www.snm.org](http://www.snm.org)). The database currently has 236 "normal" adult studies. SPECT literature of the past 20 years has more than 43 studies that look at normative issues in over 2450 patients, including 150 children from birth on (see [Table 1](#) for a sample of the some of the references<sup>(8-25)</sup>). These numbers do not include thousands of control subjects used in studies of specific neurological and psychiatric conditions. For example, Chiron et. al.<sup>(22)</sup> reported that at birth, cortical rCBFs were lower than those for adults; after birth they increased until 5 or 6 years of age to values 50%-85% higher than those for adults and thereafter decreased, reaching adult levels between 15 and 19 years. At the age of 3, however, they had the same relative blood flow patterns as adults. Mena et al.<sup>(23)</sup> report reference values for children age 6-15, as well as age related changes when comparing children to adults. Other common findings in normal studies suggest that women have generally higher perfusion than men and age, drug abuse, and smoking have a negative effect on rCBF. See [Table 1](#) for a summary of some of the major studies on normal SPECT scans.

**Table 1**  
Examples of Brain SPECT Normative Studies

# normals	First author	Date of Study	Type	Age	Significant findings
159	SNM Yale	Past-present	HMPAO	Adult	Available for research <a href="http://www.snm.org">www.snm.org</a>
77	SNM Yale	Past-present	ECD	Adult	Available for research <a href="http://www.snm.org">www.snm.org</a>
187	Slosman	2001	Xe	Adult	Male-female differences and decline with age
48	Tanaka	2001	ECD	22-95	Intersubject variability small
6 – 3 scans each	Jonsson	2000	HMPAO	Adult	Reproducibility was +/- 1.3%
53	Nakano	2000	ECD	18-87	rCBF decreases during normal aging
44	Wirestam	2000	HMPAO	Adult	fMRI and SPECT showed good agreement
26	Ernst	1999	HMPAO	Adult	fMRI and SPECT showed good agreement
13	Mena	1998	HMPAO	6-15	Normal values in children compared to adults
18	Goto	1998	HMPAO	20-81	Compare young and older scans
27	Krausz	1998	HMPAO	26-71	Aging associated with decreased rCBF
16	Schiepers	1997	ECD	Children	Safe agent for children because of favorable radiation dosimetry and stability
23 child 10 adults	Barthel	1997	ECD	4-15 27-56	Children have higher perfusion
9 – 2 scans each	Deutsch	1997	HMPAO	Adult	Good within-subject 48-hour replicability, 2.8% variability
10HMPAO 10ECD 10PET	Koyama	1997	HMPAO/ECD	Adult	Highest areas of perfusion: HMPAO – cerebellum/basal ganglia, ECD – medial occipital lobe
52	Yang	1996	HMPAO	2-85	Negative correlation between CBF and advancing age
68	Catafau	1996	HMPAO	23-75	Symmetrical rCBF distribution can be assumed independent of age
26	Kobayashi	1996	I123	0-19	Age related rCBF changes; low early infancy, increased late infancy through early childhood, and decreased and constant after puberty
42	Chiron	1992	Xe	2 days to 19 yrs	Brain development related rCBF changes of corresponding brain regions
67	Yamashita	1988	Xe	Adult	rCBF decreased with advancing age, elderly smokers showed lower rCBF than elderly nonsmokers

## POTENTIAL CLINICAL USE OF BRAIN SPECT IMAGING

According to the Society of Nuclear Medicine, the evaluation of suspected brain trauma, the evaluation of suspected dementia, the presurgical localization of epileptic foci, and the evaluation of cerebral vascular disease are acceptable indications for brain SPECT<sup>(26)</sup>. The Society of Nuclear Medicine has also published guidelines on the technical standards for performing and interpreting these studies<sup>(26)</sup>.

## BRAIN TRAUMA

There are 74 SPECT studies of brain trauma in the literature involving 1503 patients (see [Table 2](#) for a summary of some of the studies 27-48). SPECT has the potential to aid in the diagnosis and treatment of brain trauma. It can help identify if trauma is present and which brain system or systems are affected. Common findings on SPECT in brain trauma include:

- decreased perfusion over site of injury and/or opposite side (contra coup)
- decreased orbital prefrontal cortex perfusion
- decreased anterior temporal lobe perfusion (lies behind wing of sphenoid bone) and decreased posterior temporal lobe perfusion (contra coup injury within the body of the temporal lobe)
- decreased parietal lobe perfusion (at vertex of brain)
- decreased occipital lobe perfusion (hit directly or in contra coup fashion)
- focal increased perfusion over site of injury or in a contra coup area
- decreased posterior medial cerebellar perfusion
- findings often occur together - for example, decreased orbital prefrontal, decreased left and right anterior and posterior temporal lobes, decreased left and right parietal and occipital lobe perfusion. (27-28)

**Table 2**  
Examples of Brain SPECT Studies in Brain Trauma

# Patients	First Author	Study Date	Type	Age	Significant findings
24	Baulieu	2001	ECD	Adult	Valuable in predicting behavior after TBI
21	Hoffman	2001	HMPAO/MRI	Adult	Lesions common after minor TBI (77%)
16	Stepien	1999	HMPAO	Adult	Useful in early and late TBI consequences
5	Laatsch	1999	HMPAO Bef/aft rehab	Adult	rCBF changes related to neuropsychological test improvement
32	Abu-Judeh	1999	HMPAO	11-61	(1) Sensitive for mild TBI rCBF changes; (2) changes can occur without loss of consciousness; (3) more sensitive than CT; and (4) changes may explain symptoms in the absence of other imaging abnormalities.
228	Abdel-Dayem	1998	HMPAO/ECD	11-88	41 with mild TBI without LOC had normal CT, 28 had abnormal SPECT
6 – 2 times	Otte	1997	ECD and PET	Adult	Whiplash group showed decreased rCBF in parieto-occipital regions
20	Emanuelson	1997	SPECT/CT	Children	CT and SPECT similar in patients with severe injury, SPECT more sensitive in mild TBI
35	Gilkey	1997	Xe	Adult	Reduced rCBF with post traumatic headache
43	Kant	1997	HMPAO/MRI/CT	Adult	SPECT more sensitive than CT or MRI in mild TBI
136	Jacobs	1996	HMPAO – prospective	Adult	SPECT at 12 months postinjury is a reliable predictor for clinical outcome.
28	Goshen	1996	HMPAO/CT/MRI	Children	SPECT useful evaluating pediatric post-TBI
53	Sakas	1995	HMPAO	Adult	Focal zones of hyperemia were present in 38% of patients
14	Vamey	1995	HMPAO/ normal CT	Adult	Significant anterior mesial temporal and orbitofrontal hypoperfusion.
10	Bavetta	1994	HMPAO prospective	Adult	SPECT yields useful prognostic data
67	Jacobs	1994	HMPAO	Adult	(1) Correlated with severity of trauma; (2) negative initial SPECT is reliable predictor of favorable outcome; (3) a positive initial SPECT needs a follow-up scan
29	Ichise	1994	HMPAO	Adult	In chronic TBI SPECT is a more sensitive study than CT or MRI

20	Nedd	1993	HMPAO	Adult	SPECT more sensitive than CT or MRI in mild to moderate TBI.
36	Oder	1992	HMPAO	Adult	Highest correlation was between frontal flow and disinhibitive behavior
15	Roper	1991	HMPAO	Adult	SPECT can detect focal disturbances of rCBF not seen on CT

SPECT can aid in understanding patient symptomatology and assist clinicians in developing targeted treatment strategies <sup>(29-30)</sup>. For example, decreased prefrontal cortex perfusion is often associated with executive dysfunction and may be helped with psychostimulants <sup>(31)</sup>, whereas decreased temporal lobe perfusion is often associated with irritability and mood instability and may be helped with anticonvulsant medication <sup>(32)</sup>.

Literature indicates that SPECT can help evaluate perfusion abnormalities not only in cases evaluating blunt brain trauma, but also in cases of post-concussive syndrome and whiplash <sup>(33-36)</sup>. Several authors report extensive and prolonged perfusion abnormalities on SPECT after a patient has experienced relatively minor brain trauma <sup>(37-40)</sup>. Minor brain injuries that leave brain tissues grossly intact have left some patients with severe functional deficits. Brain injured patients with normal EEG, CT, and/or MRI scans often complain of headaches, memory loss, concentration difficulties, dizziness, perceptual sensitivities, and emotional lability. Such patients may be labeled as malingering, when there are significant functional abnormalities present. Several researchers have investigated the differences between functional and structural imaging techniques with patients who have sustained various degrees of head trauma.

Emanuelson et. al. <sup>(40)</sup> demonstrated differences between SPECT and structural imaging through the evaluation of 20 brain injured patients who complained of problematic post head injury symptoms (i.e., headache, dizziness, etc). Although CT and SPECT revealed similar levels of abnormality in severely brain injured patients, significant CT and SPECT differences were found in mildly injured patients. SPECT detected more affected areas of the brain than CT. Similar findings have been reported in comparisons between SPECT and EEG, CT and MRI <sup>(41-45)</sup>.

Researchers have also compared the differences between functional imaging and structural imaging in relation to clinical outcome and prognosis. Jacobs et. al. <sup>(29)</sup> used SPECT to prospectively evaluate 67 mildly to moderately brain injured patients. Each patient had a clinical evaluation and a SPECT scan within four weeks of the initial injury and three months after the first scan. Of the 33 patients who showed no significant abnormalities on their initial SPECT scan, 97% of the patients resolved their clinical symptoms within three months. By contrast, of the 34 patients who had abnormalities on their first SPECT scan, 59% of the patients continued to experience significant clinical symptoms. The positive predictive value of an abnormal initial scan was only 20/34 (59%), but if the second scan 12 months later was also abnormal the sensitivity for the repeat SPECT was 19/20 (95%). These authors suggest that negative initial SPECT studies can be a reliable predictor of a favorable clinical outcome. In another study Jacobs et al. <sup>(46)</sup> evaluated the predictive capacity of HMPAO SPECT for clinical outcome during a follow-up period of 12 months after mild head injury. They prospectively evaluated 136 patients with mild head injury who underwent initial SPECT imaging within 4 weeks after the trauma and re-evaluated patients at 2.9-3.3 months, 5.7-6.3 months, and 11.9-12.6 months postinjury. All patients with an abnormal SPECT underwent a repeat study at the subsequent time of evaluation. Patients with a previously normal SPECT scan did not undergo a repeat study. Clinical reassessments were performed as long as the earlier study had been positive or until patients were completely asymptomatic. During all follow-up evaluations, SPECT had a high sensitivity and negative predictive value, increasing from 91% and 89%, respectively, at 3 months to 100% at 6 months and at 12 months. At 12 months postinjury, the authors observed considerable improvement in the specificity and positive predictive value of SPECT (85% and 83%, respectively).

Results from functional brain imaging studies have also been associated with neuropsychological testing results. Ichise et. al. <sup>(47)</sup> suggest that SPECT may present additional objective evidence for some neuropsychological impairments that testing alone may not provide. SPECT can also demonstrate improvements in brain function as a result of cognitive rehabilitation training (CRT). Laatsch et al. <sup>(48)</sup> studied 5 patients who had acquired brain injury and initially demonstrated neuropsychological deficits and various degrees of hypoperfusion on SPECT. Following CRT, all clients were able to return to productive employment or schooling. Examination of the neuropsychological testing results revealed significant improvement in performance following CRT which were generally maintained after treatment. SPECT data revealed that, in a majority of cases, significant increases in relative cerebral blood flow redistribution was also seen. It is necessary to replicate these findings in larger groups of patients.

One of the most controversial issues in brain trauma is the issue of brain damage in the absence of

loss of consciousness. Abu-Judeh et al. (37) present SPECT findings in 32 patients who suffered mild traumatic brain injury without loss of consciousness and normal CT scans. The most common complaints were headaches in 26 patients (81%), memory deficits in 15 (47%), dizziness in 13 (41%) and sleep disorders in eight (25%). The results show that 19 (59%) had abnormal SPECT studies.

SPECT can assist in the diagnosis, prognosis, and treatment of patients who have sustained brain trauma. It is conceivable that SPECT may also uncover brain trauma in clinically confusing or complex cases because patients often fail to report or forget about significant brain injuries. One limitation of the use of SPECT in brain trauma is that often there is no prior SPECT study available for comparison. Therefore, it is often not possible to date the trauma. Remote trauma from childhood may appear similar to recent trauma. If a trauma pattern is evident on a scan it is not possible to say when it occurred.

## DEMENTIA

There are 83 studies on brain SPECT imaging and dementia in the literature involving over 4500 patients (see Table 3 for a summary of some of the studies 50-86).

**Table 3**  
Examples of Brain SPECT Studies in Dementia

# Patients/ normals	Author	Date of Study	Type	Significant Study Findings
24/12	Cappa	2001	HMPAO	Combination of neuropsychological tests and SPECT is useful in separating FTD from AD
23DLB 50AD 20NL	Lobotesis	2001	HMPAO	Temporoparietal hypoperfusion is common to both AD and DLB. Occipital hypoperfusion more frequently seen in DLB.
70 Dementia autopsy  71NL	Jagust	2001	HMPAO	SPECT can provide useful information indicating presence of AD in addition to clinical information obtained
116AD 23NLS	Tsolaki	2001	HMPAO	Decreased parietal and temporal perfusion in AD. SPECT and neuropsychological test correlation on MMSE and CAMCOG
12	Staff	2000	HMPAO Donepezil	Overall increase rCBF, especially in frontal area
30	Ashford	2000	ECD	rCBF corresponds closely to distribution of AD pathology described in autopsy studies.
40	Charpentier	2000	HMPAO	AD and FTD are differentiated by SPECT
16FLD 52AD 19subcort dem 28NLS	Sjogren	2000	HMPAO	anterior-to-posterior rCBF-SPECT ratio separated FTD group from the other dementia groups
18	Shih	1999	ECD 3Ddisplays	3D displays helpful to assess severity and progression of AD-related hypoperfusion and is potentially more reliable than the MMSE.
14DLB 14AD 14NL	Ishii	1999	HMPAO	Decreased occipital perfusion and well preserved medial temporal perfusion help distinguish DLB from AD.
69	Claus	1999	SPECT	Left temporal rCBF predicts decline in language function and survival in patients with early probable Alzheimer's disease
34/12	Arbizu	1999	HMPAO	SPECT and neuropsychological tests can distinguish controls from AD and mild to moderate grades of dementia
20	Benoit	1999	ECD	Highest correlation for MMSE was left temporoparietal area
36	McKelvey	1999	HMPAO	SPECT abnormalities assessed by visual inspection do not correlate with severity of impairment in AD
116DA 20nl	Muller	1999	HMPAO	MMSE and delayed recall test differentiated significantly between patients and controls, SPECT yielded no further differentiation
363 pro- spective	Talbot	1998	HMPAO	SPECT most useful in distinguishing AD from VD and FTD, least useful in differentiating AD from DLB
60/16	Blanco	1998	SPECT	Parietotemporal location of defective perfusion is of diagnostic value.
136	Johnson	1998	HMPAO	Useful as one aspect of the preclinical prediction of AD
34/12	Arbizu	1997	HMPAO	Temporo-parietal cortex most value in discriminating between AD and controls
261 Xe  162 HMP	Bonte	1997	Xe/HMPAO	Biopsy 54 – Sensitivity 86%, specificity, 73%; positive predictive value, 92%; and negative predictive value, 57%.
302	Hanyu	1997	I123	Sensitivity for AD was 86.3%, and specificity was 91.2%
200/119 autopsy	Jobst	1997	HMPAO/CT	SPECT alone had 89% sensitivity, 80% specificity, and 83% accuracy; and the combination of SPECT and CT was 80% sensitive, 93% specific, and 88% accurate.
19AD 21FLD	Pickut	1997	HMPAO	SPECT helpful in discriminating FLD from AD. Bifrontal

				hypoperfusion found most powerful predictor of clinical classification
27 autopsy	Read	1995	HMPAO	SPECT predicted diagnosis 92.6%, compared with clinical diagnosis 74.1%. Distinct patterns with dementia caused by AD, FTD, and Jakob-Creutzfeldt Disease
29	Wolfe	1995	I123	Temporal rCBF ratio predicted rate of decline of specific memory measures
7/7/7	Alexander	1995	SPECT	Support use of rCBF in distinguishing FLD from AD and severe depression.
71 autopsy confirmed	Jobst	1994	HMPAO	Combination of SPECT, CT and clinical criteria yielded diagnostic sensitivity of 90% and a specificity of 97%.
8AD 8FLD 8NL	Starkstein	1994	HMPAO	Specificity of changes in rCBF in diagnosis of different types of dementia
16	Engle	1993	HMPAO	Correlations were demonstrated between cerebral blood flow in the posterior brain regions and performance on tests of language, memory, attention, figure copying, judgment, and similarities.
5	Miller	1993	HMPAO	This study suggests that the right hemisphere may be primary for the control of social conduct.
29AD/78nl	Johnson	1993	HMPAO	Sensitivity 91% and specificity 86% accurately distinguishes AD patients from elderly controls
34/11	Battistin	1990	HMPAO	A positive correlation found between magnitude of the parietal deficits and severity of dementia
MCI = mild cognitive impairment AD = Alzheimer's Disease DLB = Dementia Lewy Body Type FLD = Frontal-temporal dementia MID = Multi-infarct dementia VD = Vascular dementia				

To date, autopsy reports have been the "gold standard for an Alzheimer's Disease (AD) diagnosis." However, research suggests that SPECT can be helpful when evaluating patients who are experiencing cognitive decline<sup>(50)</sup>. Functional brain imaging patterns have been associated with Alzheimer's Disease (AD; parietal and temporal lobe deficits), Frontal Lobe Dementia (FLD; frontal and temporal lobe deficits), Multi-infarct Dementia (MID; a vascular pattern of decreased activity in multiple areas), and pseudodementia (PSD; a pattern associated with depression; decreased left prefrontal cortex activity and increased thalamo-limbic activity)<sup>(51-53)</sup>. Patients diagnosed with different dementia disorders can present with similar symptomatology (i.e., social withdrawal and behavioral disinhibition)<sup>(54)</sup>. Because treatments for the different disorders vary differential diagnosis is important. Research suggests that SPECT, in combination with clinical history and other diagnostic tests can be helpful for this purpose<sup>(55)</sup>.

Numerous authors have reported bilateral decreases of activity in the parietal and temporal lobes of AD patients (56-58). Bonte et. al.<sup>(59)</sup> performed xenon SPECT studies in 261 patients and HMPAO SPECT in 162 patients with possible dementia and compared them to SPECT images of an elderly healthy control group. In each patient without AD, further classification of disease was attempted. Histopathologic correlation was available in 54 patients (with autopsy in 51, with biopsy in three). The results of the study showed SPECT diagnoses were true-positive in 37, true-negative in eight, false-positive in three, and false-negative in six patients. Sensitivity was 86%; specificity, 73%; and the positive predictive, 92%. The authors concluded that SPECT may assist in the early and late diagnoses of AD and in the differential-diagnosis of the dementias when there is a complicated or confusing clinical picture.

In a prospective study of more than 200 cases of dementia and 119 controls<sup>(60)</sup>, annual HMPAO SPECT studies, annual medial temporal lobe CT scans, and the presence of the apolipoprotein E4 (Apo E4) genotyping were used to evaluate the diagnostic potential of functional and structural neuroimaging in the differential diagnosis of dementia compared to clinical diagnoses. Autopsy histology is known for 118, of whom 80 had AD, 24 had other "non-AD" dementias, and 14 controls with no cognitive deficit. All clinical diagnoses were made according to National Institute of Neurological and Communicable Disease and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the DSM-III-R criteria, and all histopathological diagnoses according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. The diagnostic accuracy of CT alone was 85% sensitive, 78% specific, and 80% accurate; SPECT alone was 89% sensitive, 80% specific, and 83% accurate; and the combination of the two was 80% sensitive, 93% specific, and 88% accurate. The Apo E4 genotype was 74% sensitive but yielded 40% false positives in the histologically confirmed series. The diagnostic accuracy afforded by the method of CT and SPECT is better than that of any established clinical criteria and reveals that the combination of MTL atrophy and parietotemporal hypoperfusion is common in AD, much less common in other dementias, and rare in normal controls. The authors conclude that SPECT can significantly enhance diagnosis.

Julin et al. (61) compared 28 patients diagnosed with AD to eight patients diagnosed with FLD. The researchers used SPECT, MRI, and EEG to measure a number of different factors, including cerebral blood flow, brain atrophy, white matter changes, and neurophysiologic changes. The FLD patients in this study had significantly lower blood flow in the frontal lobes and significantly higher blood flow in the parietal lobes than did AD patients. Other authors report similar findings between FLD and AD patients (62-63). SPECT literature also reports differences in temporal-parietal brain functions in AD patients when compared to epilepsy, MID, Parkinson's disease, and other dementia disorders (64-66).

Jagust et al. (67) measured radioactivity densities in multiple brain regions of 50 patients to evaluate the predictive utility of rCBF measurements for AD. Although the presence of AD was confirmed by overall temporal-parietal perfusion similar to previous studies, right parietal lobe hypoperfusion was additionally a significant predictor of longer survival. Even considering such variability in the literature, some authors suggest that brain SPECT patterns have predicted cognitive decline in AD more reliably than demographic and course variables (i.e., age, prior dementia duration, and initial severity) (68-69).

Engel et al. (70) suggest that SPECT and neuropsychological testing have correlates that are clinically relevant. Correlations were demonstrated between cerebral blood flow in the posterior brain regions and performance on tests of language, memory, attention, figure copying, judgment, and similarities. Alzheimer's disease patients exhibited more language impairment than multi-infarct dementia patients. In the authors' opinion, SPECT promises to provide diagnostic information and data relevant to interpretation of neuropsychological deficits.

Apathy is a pervasive noncognitive neuropsychiatric disturbance in Alzheimer disease, which causes significant caregiver distress. Craig et al. (71) studied the relationship between rCBF and the presence and severity of the personality disturbance, apathy, in 31 individuals with Alzheimer disease. The presence of apathy was associated with more severe prefrontal and anterior temporal dysfunction. These regional cerebral perfusion relationships with apathy were independent of cognitive decline except in the dorsolateral prefrontal cortex. These results demonstrate the association of apathetic syndromes with prefrontal and anterior temporal regional brain dysfunction and are consistent with similar findings previously reported in other disorders.

The majority of the literature indicates that SPECT can assist in the differential diagnosis of dementia disorders when used in conjunction with clinical examination and neuropsychological testing. However, there are several negative studies in the literature that suggest that the predictive value of SPECT is not high enough to be used on a routine clinical basis (72-73). In addition, there are other pathological processes that can give produce patterns consistent with AD and FLD patterns, most notably brain injury that affects the prefrontal cortex pole and anterior temporal lobes (like FLD) or a brain injury that affects the temporal and parietal lobes. As with any test it is important that SPECT be used and interpreted within a clinical context.

## TEMPORAL LOBE EPILEPSY

There are 72 studies on brain SPECT imaging and temporal lobe epilepsy (TLE) in the literature involving over 2100 patients (see Table 4 for a summary of some of the studies 96-107).

**Table 4**  
Examples of Brain SPECT Studies in Epilepsy

# Patients	First Author	Study Date	Type	Age range	Significant findings
117	Hwang	2001	PET/SPECT/MRI	Adult	PET or ictal SPECT are complementary, most helpful in cases of negative MRI findings
65	Lawson	2000	HMPAO	Children	Ictal SPECT without MRI findings is useful for surgical localization
13	Avery	2000	HMPAO	Adult	Ictal SPECT more accurate than EEG/MRI
30	Sarikaya	1999	HMPAO	Children	SPECT parameters may be used for correlating with clinical parameters
118	Won	1999	PET/SPECT/MRI/video EEG	Adult	MRI, PET, and ictal SPECT correctly identified lesion in 72%, 85%, and 73% of patients
75	Oliveira	1999	ECD	Adult	Ictal SPECT easily achieved and accurately localize epileptogenic zone in temporal and extratemporal epilepsies. Ictal SPECT more sensitive and specific than interictal SPECT
46 papers, meta-	Devous	1998	multiple	all	SPECT localization in patients with temporal lobe seizures were 0.44

analysis					(interictal), 0.75 (postictal) and 0.97 (ictal). False-positive rates low relative to diagnostic evaluation (7.4% for interictal and 1.5% for postictal studies)
59	O'Brien	1998	HMPAO	Children	Provides specific localizing information in a high proportion of these patients
20	Guillon	1998	HMPAO	Adult	Interictal SPECT correlated with EEG irritative zone.
14	Menzel	1996	ECD	Children	Interictal SPECT showed hypoperfusion areas in 80%. Ictal rCBF SPECT informative in all
45	Matsuda	1996	HMPAO	Adult	Interictal SPECT gives useful information about epileptic focus and antiepileptic drugs
20	Rodrigues	1996	HMPAO	Adult	Focal hypoperfusion in 93%, ictal hyperperfusion in all
30	Ho	1996	HMPAO	Adult	Ictal SPECT helpful for subclassification of TLE, clinical features relatively unhelpful
21	Alper	1995	HMPAO	Children	Pathology on SPECT, CT, and EEG were 67%, 38%, and 52%, respectively. SPECT showed congruent, or more extensive, lesions in 8 patient with CT lesions. Six of 13 with normal CT, had abnormal SPECT.
55	Otsubo	1995	HMPAO	Children	Interictal/postictal SPECT can lead to greater accuracy in localizing epileptic foci
28	Duncan	1993	HMPAO	Adult	Ictal/postictal SPECT reliable for presurgical localization of complex partial seizures
79	Uvebrant	1991	HMPAO	Children	SPECT relevant information in 79% of cases, MRI 49% and CT 36%
34	Shen	1990	HMPAO	Adult	Intericta/ictal SPECT easily obtained and provides reliable information in presurgical evaluation of intractable epilepsy

Temporal Lobe Epilepsy (TLE) is one of the most frequently encountered chronic epileptic disorders and has been associated with numerous psychiatric symptoms, such as depressed mood, anergia, irritability, euphoric mood, atypical pain, insomnia, fear, and anxiety<sup>(88)</sup>. The medial aspects of the temporal lobes are frequently involved in TLE and they are difficult to evaluate with routine EEG studies and therefore may be missed. Ictal SPECT and, to a lesser degree, interictal and peri-ictal SPECT have been used to accurately identify seizure foci. SPECT findings in epilepsy most often reveal focal decreased perfusion in the interictal phase and focal increased perfusion in the ictal phase of a seizure<sup>(89-94)</sup>. In a review of 30 studies, Devous et al.<sup>(89)</sup> found that SPECT localization in patients with temporal lobe seizures were 0.44 (interictal), 0.75 (postictal) and 0.97 (ictal). False-positive rates were low.

Shen et al.<sup>(94)</sup> utilized brain SPECT imaging to evaluate 34 patients who eventually underwent a temporal lobectomy for medically intractable complex partial seizures. Consistent with previous findings, patients in the interictal phase revealed decreased regional cerebral perfusion in the temporal lobe. These abnormalities corresponded with the eventual site of surgery in 73% of their patients. Ninety-three percent of their patients also displayed increased perfusion on SPECT during the ictal phase, which also corresponded with the eventual site of surgery. Sixty-nine percent of the patients had both increased cerebral perfusion on the ictal scan and decreased cerebral perfusion on the interictal scan, which corresponded to the eventual site of surgery. Duncan et al.<sup>(95)</sup> report similar sequences of ictal (increased) and post-ictal (decreased) temporal lobe perfusion in their study of 28 patients with medically intractable complex partial seizures. Subsequent temporal lobe surgery on the hemisphere indicated by SPECT was again successful (i.e., 90% reduction in seizure frequency) in 96%<sup>(27/28)</sup> of their patients.

Brain SPECT findings in epilepsy research have correlated well with other techniques and may contribute additional information. A number of authors have evaluated the utility of brain SPECT and various structural techniques for the localization of seizure foci<sup>(96-102)</sup>. Otsubo et al.<sup>(90)</sup> reviewed EEG, CT, MRI, and SPECT imaging data obtained from 28 children with intractable seizures. In their study, brain SPECT accurately localized epileptogenic abnormalities found with MRI, CT, and EEG. However, the SPECT studies additionally showed interictal decreases of rCBF that corresponded with the temporal epileptogenic zone in 68% (15/22) of the patients. Uvebrant et al.<sup>(102)</sup> compared the



value of SPECT to neuropsychiatric evaluations in their study of 79 children. Of the 56 children investigated for epilepsy, SPECT yielded clinically relevant information consistent with a diagnosis of epilepsy in 79% of their cases. MRI and CT yielded clinically relevant information in 49% and 36% of their cases, respectively. Although neither functional nor structural imaging can clarify the etiology of epilepsy, SPECT may provide information that associates the distribution of functional lesions with the behavioral manifestations associated with epilepsy. Patients with epilepsy may have functional pathophysiological deficits of otherwise grossly intact brain tissue (97-99). In 45 patients Matsuda et al. (98) found that SPECT gave useful information about interictal cerebral blood flow around an epileptic focus and about the effects of antiepileptic drugs on brain function in TLE. Ictal SPECT may also be helpful for subclassification of temporal lobe seizures (102), whereas clinical features are relatively unhelpful. Perfusion patterns provide insight into preferential pathways of seizure propagation in the subtypes of TLE.

One of the major drawbacks of SPECT is that several studies report that interictal PET may be as sensitive as ictal SPECT (104-105). It is easier to perform studies in the interictal phase where PET is available. Yet, it is clear that SPECT may add to the clinical evaluation of temporal lobe function by identifying an area(s) of abnormality, showing deficits not seen by EEG, and possibly by shedding light on why anticonvulsants are useful for broad neuropsychiatric indications.

## CONCLUSIONS AND CAUTIONS

There is a converging body of literature on the usefulness of brain SPECT imaging in brain trauma, dementia, and temporal lobe epilepsy. However, a number of issues need be addressed before SPECT, or any other functional imaging technique, can become a standard evaluation tool. The uncertainty of false positive and false negative readings is of particular concern. As more integrative studies are conducted, the actual statistical significance of false positive and false negative readings with different diagnoses will become clearer. Furthermore, brain SPECT imaging, as with any clinical tool, should always be evaluated within the context of a patient's clinical history and examination.

Because of the variability of scan procedures and camera sensitivity, physician training and experience is of primary concern when evaluating the usefulness of SPECT. Outdated single-headed cameras do not have the same level of resolution as the multi-headed cameras. It is also possible that less experienced physicians will read a scan as "normal," while more experienced physicians will discover clear areas of concern on the same scan (or vice-versa). Although image resolution and rater variability are concerns for reading functional and structural imaging studies, the importance of experience and standardized rating scales are becoming increasingly evident when evaluating the utility of brain SPECT imaging.

In order to utilize SPECT technology effectively, three factors should be considered at minimum. It is important to have a high-resolution SPECT camera (i.e., a dual or a triple head camera), a nuclear medicine physician skilled in reading brain studies for neuropsychiatric purposes, and a psychiatrist who understands how to utilize the technology to properly integrate findings and inform treatment.

## REFERENCES

1. Holman BL, Devous MD Sr. Functional brain SPECT: the emergence of a powerful clinical method. *J Nucl Med* 1992; 33:1888-1904  
[back](#)
2. Catafau AM, Lomena FJ, Pavia J, Parellada E, Bernardo M, Setoain J, Tolosa E. Regional cerebral blood flow pattern in normal young and aged volunteers: a 99mTc-HMPAO SPET study. *Eur J Nucl Med* 1996 Oct;23(10):1329-37  
[back](#)
3. Kawashima R, Koyama M, Ito H, Yoshioka S, Sato K, Ono S, Goto R, Sato T, Fukuda H. Normal cerebral perfusion of 99mTc-ECD brain SPECT--evaluation by an anatomical standardization technique. *Kaku Igaku* 1996 Jan;33(1):69-72  
[back](#)
4. Datz FL, Patch GG, Arias JM, Morton KA. *Nuclear Medicine: A teaching profile*. St. Louis, MO, Moseby-Yearbook, 1992  
[back](#)
5. Kuperman K, Gaffney GR, Hamdan-Allen G, Preston DF, Venkatesh L. *Neuroimaging in Child and Adolescent Psychiatry*. *J Am Acad Child Adolesc Psychiatry* 1990; 29:159-172  
[back](#)
6. George, MS. *Neuroactivation and Neuroimaging with SPET*. New York, NY, Springer-Verlag, 1991  
[back](#)

7. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology: Assessment of brain SPECT 1996; 46:278-285  
[back](#)
8. Slosman DO, Chicherio C, Ludwig C, Genton L, de Ribaupierre S, Hans D, Pichard C, Mayer E, Annoni JM, de Ribaupierre A. 133Xe spect cerebral blood flow study in a healthy population: determination of t-scores. J Nucl Med 2001 Jun;42(6):864-70  
[back](#)
9. Tanaka F, Vines D, Tsuchida T, Freedman M, Ichise M. Normal patterns on 99mTc-ECD brain SPECT scans in adults. J Nucl Med 2000 Sep;41(9):1456-64  
[back](#)
10. Jonsson C, Pagani M, Johansson L, Thurffjell L, Jacobsson H, Larsson SA. Reproducibility and repeatability of 99Tcm-HMPAO rCBF SPET in normal subjects at rest using brain atlas matching. Nucl Med Commun 2000 Jan;21(1):9-18  
[back](#)
11. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Effects of healthy aging on the regional cerebral blood flow measurements using 99mTc-ECD SPECT assessed with statistical parametric mapping]. Nippon Ronen Igakkai Zasshi 2000 Jan;37(1):49-55  
[back](#)
12. Wirestam R, Ryding E, Lindgren A, Geijer B, Ostergaard L, Andersson L, Holtas S, Stahlberg F. Regional cerebral blood flow distributions in normal volunteers: dynamic susceptibility contrast MRI compared with 99mTc-HMPAO SPECT. J Comput Assist Tomogr 2000 Jul-Aug;24(4):526-30  
[back](#)
13. Ernst T, Chang L, Itti L, Speck O. Correlation of regional cerebral blood flow from perfusion MRI and spect in normal subjects. Magn Reson Imaging 1999 Apr;17(3):349-54  
[back](#)
14. Goto R, Kawashima R, Ito H, Koyama M, Sato K, Ono S, Yoshioka S, Fukuda H. A comparison of Tc-99m HMPAO brain SPECT images of young and aged normal individuals. Ann Nucl Med 1998 Dec;12(6):333-9  
[back](#)
15. Krausz Y, Bonne O, Gorfine M, Karger H, Lerer B, Chisin R. Age-related changes in brain perfusion of normal subjects detected by 99mTc-HMPAO SPECT. Neuroradiology 1998 Jul;40(7):428-34  
[back](#)
16. Schiepers C, Verbruggen A, Casaer P, De Roo M. Normal brain perfusion pattern of technetium-99m-ethylcysteinate dimer in children. J Nucl Med 1997 Jul;38(7):1115-20  
[back](#)
17. Barthel H, Wiener M, Dannenberg C, Bettin S, Sattler B, Knapp WH. Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using 99mTc-ECD. Eur J Nucl Med 1997 Oct;24(10):1245-52  
[back](#)
18. Deutsch G, Mountz JM, Katholi CR, Liu HG, Harrell LE. Regional stability of cerebral blood flow measured by repeated technetium-99m-HMPAO SPECT: implications for the study of state-dependent change. J Nucl Med 1997 Jan;38(1):6-13  
[back](#)
19. Koyama M, Kawashima R, Ito H, Ono S, Sato K, Goto R, Kinomura S, Yoshioka S, Sato T, Fukuda H. SPECT imaging of normal subjects with technetium-99m-HMPAO and technetium-99m-ECD. J Nucl Med 1997 Apr;38(4):587-92  
[back](#)
20. Yang D, Jinnouchi S, Nagamachi S, Ohnishi T, Futami S, Kodama T, Hoshi H, Watanabe K. Normal distribution of CBF with advancing age measured by HMPAO SPECT. Nippon Igaku Hoshasen Gakkai Zasshi 1996 Oct;56(12):860-5  
[back](#)
21. Kobayashi A, Ito M, Shiraishi H, Kishi K, Sejima H, Haneda N, Uchida N, Sugimura K. A quantitative study of regional cerebral blood flow in childhood using 123I-IMP-SPECT: with emphasis on age-related changes]. No To Hattatsu 1996 Nov;28(6):501-7  
[back](#)
22. Chiron C, Raynaud C, Maziere B, Zilbovicius M, Laflamme L, Masure MC, Dulac O, Bourguignon M, Syrota A. Changes in regional cerebral blood flow during brain maturation in children and adolescents. J Nucl Med 1992 May;33(5):696-703  
[back](#)
23. Mena, Francisco J et al. Children Normal HMPAO Brain SPECT. Alasbimn Journal1(1):

September 1998. <<http://www.alasbimjournal.cl/revistas/1/children.htm>>

[back](#)

24. Yamashita K, Kobayashi S, Yamaguchi S, Kitani M, Tsunematsu T. Effect of smoking on regional cerebral blood flow in the normal aged volunteers. *Gerontology* 1988;34(4):199-204  
[back](#)
25. Rodriguez G, Warkentin S, Risberg J, Rosadini G. Sex differences in regional cerebral blood flow. *J Cereb Blood Flow Metab* 1988 Dec;8(6):783-9  
[back](#)
26. Juni JE, Waxman,AD, Devous MD, et. al. Society of Nuclear Medicine Procedure Guideline for Perfusion Single Photon Emission Computed Tomography (SPECT) Using Tc-99m Radiopharmaceuticals. Society of Nuclear Medicine, Brain Imaging Council, 1999.  
[back](#)
27. Varney,Nils R; Bushnell,David L; Nathan,Mark; Kahn,Daniel; Roberts,Richard; Rezai,Karim; Walker,Wayne; Kirchner,Peter: NeuroSPECT correlates of disabling mild head injury: preliminary findings. *J. Head Trauma Rehabil.* 1995, 10, 18-28.  
[back](#)
28. Fumeya H; Ito K; Yamagiwa O; Funatsu N; Okada T; Asahi S; Ogura H; Kubo M; Oba T: Analysis of MRI and SPECT in patients with acute head injury. *Acta Neurochir Suppl (Wien)* 1990;51:283-5  
[back](#)
29. Jacobs A, Put E, Ingels M, Bossuyt A. Prospective evaluation of technetium-99m-HMPAO SPECT in mild and moderate traumatic brain injury. *J Nucl Med* 1994; 35:942-947  
[back](#)
30. Baulieu F, Fournier P, Baulieu JL, Dalonneau M, Chiaroni P, Eder V, Pottier JM, Legros B.: Technetium-99m ECD single photon emission computed tomography in brain trauma: comparison of early scintigraphic findings with long-term neuropsychological outcome. *J Neuroimaging* 2001 Apr;11(2):112-20  
[back](#)
31. Kim BN, Lee JS, Cho SC, Lee DS. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. *Yonsei Med J* 2001 Feb;42(1):19-29  
[back](#)
32. Morikawa M, Iida J, Tokuyama A, Tatsuda H, Matsumoto H, Kishimoto T. Successful treatment using low-dose carbamazepine for a patient of personality change after mild diffuse brain injury. *Nihon Shinkei Seishin Yakurigaku Zasshi* 2000 Oct;20(4):149-53  
[back](#)
33. Kant R, Smith-Seemiller L, Isaac G, Duffy J. Tc-HMPAO SPECT in persistent post-concussion syndrome after mild head injury: comparison with MRI/CT. *Brain Inj* 1997; 11:115-124  
[back](#)
34. Gilkey SJ, Ramadan NM, Aurora TK, Welch KM. Cerebral blood flow in chronic post-traumatic headache. *Headache* 1997; 37:583-587  
[back](#)
35. Otte A, Ettlin TM, Nitzsche EU, et. al. PET and SPECT in whiplash syndrome: a new approach to a forgotten brain? *J Neurol Neurosurg Psychiatry* 1997; 63:368-372  
[back](#)
36. Ichise M, Chung DG, Wang P, Wortzman G, Gray BG, Franks W. Technetium-99m-HMPAO SPECT, CT and MRI in the evaluation of patients with chronic traumatic brain injury: a correlation with neuropsychological performance. *J Nucl Med* 1994; 35:217-226  
[back](#)
37. Abu-Judeh HH, Parker R, Singh M, et. al. SPET brain perfusion imaging in mild traumatic brain injury without loss of consciousness and normal computed tomography. *Nucl Med Commun* 1999; 20:505-510  
[back](#)
38. Abdel-Dayem HM, Abu-Judeh H, Kumar M, et. al. SPECT brain perfusion abnormalities in mild or moderate traumatic brain injury. *Clin Nucl Med* 1998; 23:309-317  
[back](#)

39. Hofman PA, Stapert SZ, van Kroonenburgh MJ, Jolles J, de Kruijk J, Wilmink JT. MR imaging, single-photon emission CT, and neurocognitive performance after mild traumatic brain injury. *AJNR Am J Neuroradiol* 2001 Mar;22(3):441-9  
[back](#)
40. Emanuelson IM, von Wendt L, Bjure J, Wiklund LM, Uvebrant P. Computed tomography and single-photon emission computed tomography as diagnostic tools in acquired brain injury among children and adolescents. *Dev Med Child Neurol* 1997; 39:502-507  
[back](#)
41. Goshen E, Zwas ST, Shahar E, Tadmor R. The role of 99Tcm-HMPAO brain SPET in paediatric traumatic brain injury. *Nucl Med Commun* 1996; 17:418-422  
[back](#)
42. Nedd K, Sfakianakis G, Ganz W, et. al. 99mTc-HMPAO SPECT of the brain in mild to moderate traumatic brain injury patients: compared with CT--a prospective study. *Brain Inj* 1993; 7:469-479  
[back](#)
43. Bavetta S, Nimmon CC, White J, et. al. A prospective study comparing SPET with MRI and CT as prognostic indicators following severe closed head injury. *Nucl Med Commun* 1994; 15:961-968  
[back](#)
44. Stepien A; Maksymiuk G; Skrzyński S; Chmielowski K; Podgorski JK; Kwasucki J; Pietrzykowski J: Assessment of regional blood flow in patients after mild head trauma, *Neurol Neurochir Pol* 1999 Jan-Feb;33(1):119-29  
[back](#)
45. Roper SN, Mena I, King W, Schweitzer J, Garrett K, Mehringer CM, McBride D  
An analysis of cerebral blood flow in acute closed head injury using 99mTc HMPAO SPECT and CT. *The Journal of Nuclear Medicine J Nucl Med* 32:9, 1684-1687, 1991  
[back](#)
46. Jacobs A, Put E, Ingels M, Put T, Bossuyt A. One-year follow-up of technetium-99m-HMPAO SPECT in mild head injury. *J Nucl Med* 1996 Oct;37(10):1605-9  
[back](#)
47. Ichise M, Chung DG, Wang P, Wortzman G, Gray BG, Franks W. Technetium-99m-HMPAO SPECT, CT and MRI in the evaluation of patients with chronic traumatic brain injury: a correlation with neuropsychological performance. *J Nucl Med* 1994 Feb;35(2):217-26  
[back](#)
48. Laatsch L, Pavel D, Jobe T, Lin Q, Quintana JC. Incorporation of SPECT imaging in a longitudinal cognitive rehabilitation therapy programme. *Brain Inj* 1999 Aug;13(8):555-70  
[back](#)
49. Oder W, Goldenberg G, Spatt J, Podreka I, Binder H, Deecke L: Behavioural and psychosocial sequelae of severe closed head injury and regional cerebral blood flow: a SPECT study. *Journal of Neurology, Neurosurgery and Psychiatry* 1992; 55:475-480  
[back](#)
50. Newberg AB, Alavi A, Payer F. Single photon emission computed tomography in Alzheimer's disease and related disorders. *Neuroimaging Clin N Am* 1995; 5:103-123  
[back](#)
51. Alexander GE, Prohovnik I, Sackeim HA, Stern Y, Mayeux R. Cortical perfusion and gray matter weight in frontal lobe dementia. *J Neuropsychiatry Clin Neurosci* 1995; 7:188-196  
[back](#)
52. Miller BL, Cummings JL, Villanueva-Meyer J, Boone K, Mena I  
Frontal lobe degeneration: Clinical, neuropsychological and SPECT characteristics. *Neurology*, 41:1374-1382, 1991  
[back](#)
53. Lesser I, Mena I, Boone K, Miller B, Mehringer CMM, Wohl M. Reduction of cerebral blood flow in older depressed patients. *Archives of General Psychiatry* 1994;51:677-686  
[back](#)
54. Rapoport, SI. Positron Emission Tomography in relation to disease pathogenesis: a critical review. *Cerebrovasc Brain Metab Rev* 1991; 3:297  
[back](#)
55. Read SL, Miller BL, Mena I, Kim R, Itabashi H, Darby A. SPECT in dementia: clinical

and pathological correlation. *J Am Geriatr Soc* 1995 Nov;43(11):1243-7

[back](#)

56. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O'Brien JT. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. *Neurology* 2001 Mar 13;56(5):643-9  
[back](#)
57. Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects. *Am J Alzheimers Dis Other Demen* 2001 Jan-Feb;16(1):21-31  
[back](#)
58. Blanco A, Alberca R, Marques, Lopez Dominguez JM, Gil Neciga E, Carrizosa E. Usefulness of SPECT in the study of Alzheimer's disease. *Neurologia* 1998 Feb;13(2):63-8  
[back](#)
59. Bonte FJ, Weiner MF, Bigio EH, White CL. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. *Radiology* 1997; 202:793-797  
[back](#)
60. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging. *Int Psychogeriatr* 1997;9 Suppl 1:191-222  
[back](#)
61. Julin P, Wahlund LO, Basun H, Persson A, Mare K, Rudberg U. Clinical diagnosis of frontal lobe dementia and Alzheimer's disease: relation to cerebral perfusion, brain atrophy and electroencephalography. *Dementia* 1995; 6:142-147  
[back](#)
62. Starkstein SE, Miglioreli R, Teson A, et. al. Specificity of changes in cerebral blood flow in patients with frontal lobe dementia. *J Neurol Neurosurg Psychiatry* 1994; 57:790-796  
[back](#)
63. Sjogren M, Gustafson L, Wikkelso C, Wallin A. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. *Dement Geriatr Cogn Disord* 2000 Sep-Oct;11(5):275-85  
[back](#)
64. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. *J Nucl Med* 1992; 33:181-185  
[back](#)
65. Battistin L, Pizzolato G, Dam M. Regional cerebral blood flow study with 99mTc-hexamethyl-propyleneamine oxime single photon emission computed tomography in Alzheimer's and multi-infarct dementia. *Eur Neurol* 1990; 30:296-301  
[back](#)
66. Passero S, Rocchi R, Vatti G, Burgalassi L, Battistini N. Quantitative EEG mapping, regional cerebral blood flow, and neuropsychological function in Alzheimer's disease. *Dementia* 1995; 6:148-156  
[back](#)
67. Jagust WJ, Haan MN, Reed BR, Eberling JL. Brain perfusion imaging predicts survival in Alzheimer's disease. *Neurology* 1998; 51:1009-1013  
[back](#)
68. Wolfe N, Reed BR, Eberling JL, Jagust WJ. Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer's disease. *Arg Neurol* 1995; 52:257-262  
[back](#)
69. Johnson KA; Jones K; Holman BL; Becker JA; Spiers PA; Satlin A; Albert MS: Preclinical prediction of Alzheimer's disease using SPECT *Neurology*, 50(6):1563-71 1998 Jun  
[back](#)
70. Engel P, Cummings JL, Villanueva-Meyer J, Mena I. Single photon emission computed tomography in dementia syndromes: Relationship of perfusion and cognitive deficits. *J of*

Geriatr Psychiatry and Neurol 1993;6:144-151

[back](#)

71. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996 Nov;53(11):1116-20  
[back](#)
72. McKelvey R, Bergman H, Stern J, Rush C, Zahirney G, Chertkow H. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 1999 Feb;26(1):23-8  
[back](#)
73. Muller H, Moller HJ, Stippel A, Fric M, Grunwald F, Laux G, Klemm E, Biersack HJ. SPECT patterns in probable Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249(4):190-6  
[back](#)
74. Charpentier P, Lavenu I, Defebvre L, Duhamel A, Lecouffe P, Pasquier F, Steinling M. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry 2000 Nov;69(5):661-3  
[back](#)
75. Arbizu J, Larumbe R, Gamez C, Marti J, Martinez-Lage J, Richter J. Correlations between brain SPECT and neuropsychology assessments in mild and moderate stages of Alzheimer's disease. Rev Esp Med Nucl 1999 Aug;18(4):252-60  
[back](#)
76. Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA. Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer's disease. J Nucl Med 2000 Jan;41(1):57-64  
[back](#)
77. Benoit M, Dygai I, Migneco O, Robert PH, Bertogliati C, Darcourt J, Benoliel J, Aubin-Brunet V, Pringuey D. Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 1999 Nov-Dec;10(6):511-7  
[back](#)
78. Cappa A, Calcagni ML, Villa G, Giordano A, Marra C, De Rossi G, Puopolo M, Gainotti G. Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment. J Neurol Neurosurg Psychiatry 2001 Jan;70(1):22-7  
[back](#)
79. Hanyu H, Asano T, Abe S, Arai H, Takasaki M, Shindo H, Abe K. Single photon emission computed tomography in the diagnosis of Alzheimer's disease. Nippon Ronen Igakkai Zasshi 1997 Jun;34(6):468-73  
[back](#)
80. Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999 Jul 22;53(2):413-6  
[back](#)
81. Jagust W; Thisted R; Devous MD; Van Heertum R; Mayberg H; Jobst K; Smith AD; Borys N: SPECT perfusion imaging in the diagnosis of Alzheimer's disease: A clinical-pathologic study. Neurology 2001 Apr 10;56(7):950-6  
[back](#)
82. Johnson KA, Kijewski MF, Becker JA, Garada B, Satlin A, Holman BL. Quantitative brain SPECT in Alzheimer's disease and normal aging. J Nucl Med 1993 Nov;34(11):2044-8  
[back](#)
83. Pickut BA, Saerens J, Marien P, Borggreve F, Goeman J, Vandevivere J, Vervaet A, Dierckx R, de Deyn PP. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. J Nucl Med 1997 Jun;38(6):929-34  
[back](#)
84. Shih WJ, Ashford JW, Coupal JJ, Ryo YU, Stipp V V, Magoun SL, Gross K. Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer's disease Clin Nucl Med 1999 Oct;24(10):773-7

- [back](#)
85. Staff RT, Gemmell HG, Shanks MF, Murray AD, Venneri A. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy. Nucl Med Commun 2000 Jan;21(1):37-41  
[back](#)
86. Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 1998 Mar;64(3):306-13  
[back](#)
87. Miller BL, Chang L, Mena I, Boone K, Lesser IM. Progressive right frontotemporal degeneration: Clinical, neuropsychological and SPECT characteristics. Dementia 1993;4:204-213  
[back](#)
88. Blumer, D. Personality Disorders In Epilepsy. In Neuropsychiatry of Personality Disorders. Edited by Ratey J. Cambridge, MA: Blackwell Science, 1995  
[back](#)
89. Devous MD Sr; Thisted RA; Morgan GF; Leroy RF; Rowe CC: *SPECT brain* imaging in epilepsy: a meta-analysis. J Nucl Med, 39(2):285-93 1998 Feb  
[back](#)
90. Lawson JA, O'Brien TJ, Bleasel AF, Haindl W, Vogrin S, Cook MJ, Bye AM. Evaluation of SPECT in the assessment and treatment of intractable childhood epilepsy. Neurology 2000 Nov 14;55(9):1391-3  
[back](#)
91. Oliveira AJ, da Costa JC, Hilario LN, Anselmi OE, Palmieri A. Localization of the epileptogenic zone by ictal and interictal SPECT with 99mTc-ethyl cysteinate dimer in patients with medically refractory epilepsy. Epilepsia 1999 Jun;40(6):693-702  
[back](#)
92. Menzel C, Steidele S, Grunwald F, Hufnagel A, Pavics L, Elger CE, Biersack HJ. Evaluation of technetium-99m-ECD in childhood epilepsy. J Nucl Med 1996 Jul;37(7):1106-12  
[back](#)
93. Guillon B, Duncan R, Biraben A, Bernard AM, Vignal JP, Chauvel P. Correlation between interictal regional cerebral blood flow and depth-recorded interictal spiking in temporal lobe epilepsy. Epilepsia 1998; 39:67-76  
[back](#)
94. Shen W, Lee BI, Park HM, et. al. HIPDM-SPECT brain imaging in the presurgical evaluation of patients with intractable seizures. J Nucl Med 1990; 31:1280-1284  
[back](#)
95. Duncan R, Patterson J, Roberts R, Hadley DM, Bone I. Ictal/postictal SPECT in the pre-surgical localization of complex partial seizures. J Neurol Neurosurg Psychiatry 1993; 56:141-148  
[back](#)
96. Otsubo H, Hwang PA, Hoffman HJ, et. al. Neuroimaging studies in children with temporal lobectomy. Childs Nerv Syst 1995; 11:281-287  
[back](#)
97. Alper E, Koksal N, Hacimustafaoglu M, Akbunar T, Eralp O. Tc-99m HMPAO brain SPECT compared to CT and EEG after seizures in childhood. Clin Nucl Med 1995 Sep;20(9):803-6  
[back](#)
98. Matsuda H, Fukuchi T, Onuma T, Ishida S, Uesugi H. Interictal cerebral and cerebellar blood flow in temporal lobe epilepsy as measured by a noninvasive technique using Tc-99m HMPAO. Clin Nucl Med 1996 Nov;21(11):867-72  
[back](#)
99. Hwang SI, Kim JH, Park SW, Han MH, Yu IK, Lee SH, Lee DS, Lee SK, Chung CK, Chang KH. Comparative analysis of MR imaging, positron emission tomography, and ictal single-photon emission CT in patients with neocortical epilepsy. AJNR Am J Neuroradiol 2001 May;22(5):937-46  
[back](#)
100. O'Brien TJ, Zupanc ML, Mullan BP, O'Connor MK, Brinkmann BH, Cicora KM, So EL. The practical utility of performing peri-ictal SPECT in the evaluation of children with

partial epilepsy. *Pediatr Neurol* 1998 Jul;19(1):15-22

[back](#)

101. Hara M, Takahashi M, Kojima A, et. al. Single photon emission computed tomography in children with idiopathic seizures. *Radiat Med* 1991; 9:185-189  
[back](#)
102. Uvebrant P, Bjure J, Hedstrom A, Ekholm S. Brain single photon emission computed tomography (SPECT) in neuropediatrics. *Neuropediatrics* 1991; 22:3-9  
[back](#)
103. Ho SS, Berkovic SF, McKay WJ, Kalnins RM, Bladin PF. Temporal lobe epilepsy subtypes: differential patterns of cerebral perfusion on ictal SPECT. *Epilepsia* 1996 Aug;37(8):788-95  
[back](#)
104. Markand ON, Salanova V, Worth R, Park HM, Wellman HN. Comparative study of interictal PET and ictal SPECT in complex partial seizures. *Acta Neurol Scand* 1997 Mar;95(3):129-36  
[back](#)
105. Won HJ, Chang KH, Cheon JE, Kim HD, Lee DS, Han MH, Kim IO, Lee SK, Chung CK. Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. *AJNR Am J Neuroradiol* 1999 Apr;20(4):593-9  
[back](#)
106. Avery RA, Zupal IG, Stokking R, Studholme C, Corsi M, Seibyl JP, Spencer SS. Decreased cerebral blood flow during seizures with ictal SPECT injections. *Epilepsy Res* 2000 Jun;40(1):53-61  
[back](#)
107. Rodrigues M, Botelho MM, Fonseca AT, Peter JP, Pimentel T, Vieira MR. Combined study of <sup>99m</sup>Tc-HMPAO SPECT and computerized electroencephalographic topography (CET) in patients with medically refractory complex partial epilepsy. *Ann Nucl Med* 1996 Feb;10(1):113-8  
[back](#)

[Abstracts](#) | [Introduction](#) | [Potential Clinical Use of Brain SPECT Imaging](#) | [Brain trauma](#) | [Dementia](#) | [Temporal Lobe Epilepsy](#) | [Conclusions and Cautions](#) | [References](#) | [Print Version](#)

Sitio desarrollado por SISIB - Universidad de Chile